Previous 10 | Next 10 |
Nano-cap BiondVax Pharmaceuticals (NASDAQ:BVXV) has more than doubled in the pre-market on above-average volume after announcing the signing of definitive agreements with two German institutes for the development and commercialization of COVID-19 nanosized antibodies. The agreements with Max ...
BiondVax Pharmaceuticals (NASDAQ:BVXV) +55% signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany. BioRestorative Therapi...
BiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany - Max Planck Institute of Biophysical Chemistry, ...
Biondvax Pharmaceuticals (NASDAQ:BVXV): Q3 GAAP EPS of -NIS 0.02. As of September 30, 2021, BiondVax had cash and cash equivalents of NIS 34.6M as compared to NIS 39.9M as of June 30, 2021. Press Release For further details see: Biondvax Pharmaceuticals reports Q3 results
BiondVax announces Third Quarter 2021 Financial Results and Provides Business Update PR Newswire JERUSALEM , Nov. 30, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing and commercializing innovative ...
BiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Business Update PR Newswire JERUSALEM, Israel , Nov. 24, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing and c...
BiondVax to Present at H.C. Wainwright 7th Annual Israel Conference PR Newswire JERUSALEM , Nov. 15, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), which focuses on developing, manufacturing and commercializing innovative products for the ...
Energous (NASDAQ:WATT) +35% granted FCC approval for unlimited Distance over-the-air wireless charging Edesa Biotech (NASDAQ:EDSA) +29% reports favorable mortality reductions in COVID-19 study InflaRx (NASDAQ:IFRX) +21% after EUR 43.7M vilobelimab development grant En...
BiondVax advances its growth strategy towards a new pipeline based on innovative VHH antibodies Signs term sheet for a broad-based strategic collaboration with Max Planck Society and University Medical Center Göttingen, Germany · Max Planck Society (MPG), one of th...
BiondVax Announces Second Quarter 2021 Financial Results and Provides Business Update PR Newswire JERUSALEM , Aug. 26, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ulti...
News, Short Squeeze, Breakout and More Instantly...
BiondVax Pharmaceuticals Ltd. Company Name:
BVXV Stock Symbol:
NASDAQ Market:
BiondVax (NASDAQ: BVXV) , a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has revamped its senior management team and pharmaceuticals...
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. (“Scinai ”). In the past two years, the Company ...
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...